Related Experiment Video

Updated: Sep 28, 2025

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.1K

Monoamine oxidase A drives neuroendocrine differentiation in prostate cancer

Xue Shui1, Xuehua Ren2, Rong Xu3

  • 1Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, 710032, Xi'an, Shaanxi, China; School of Basic Medical Sciences, Medical College of Yan'an University, 580 Bao-Ta Street, 716000, Yanan, China.

Biochemical and Biophysical Research Communications
|March 29, 2022
PubMed

Insights

Monoamine oxidase A (MAOA) drives neuroendocrine prostate cancer (NEPC) progression and treatment resistance. Inhibiting MAOA may offer a new strategy to combat advanced prostate cancer (PCa) and prevent treatment failure.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Neuroendocrine transdifferentiation (NED) in prostate cancer (PCa) leads to treatment failure.
  • The molecular drivers of treatment-induced NEPC are not fully understood.
  • Elevated monoamine oxidase A (MAOA) is implicated in PCa proliferation, stemness, and metastasis.

Purpose of the Study:

  • To investigate the role of MAOA in enzalutamide-induced NED in PCa.
  • To elucidate the signaling pathways involved in MAOA-mediated NED.
  • To evaluate the therapeutic potential of MAOA inhibition in CRPC.

Main Methods:

  • Generation of an enzalutamide-induced NED cell model.
  • Assessment of MAOA expression and its requirement for neuroendocrine marker expression.
  • Analysis of the MAOA/mTOR/HIF-1α signaling axis.

Main Results:

  • MAOA expression significantly increased upon long-term enzalutamide exposure.
  • MAOA was essential for neuroendocrine marker expression during NED.
  • Enzalutamide induced NED via the MAOA/mTOR/HIF-1α pathway.
  • MAOA inhibition with clorgyline (CLG) showed potential benefits for CRPC patients.

Conclusions:

  • MAOA plays a critical role in treatment-induced NED of prostate cancer.
  • The MAOA/mTOR/HIF-1α axis is a key mediator of this process.
  • MAOA inhibition represents a promising therapeutic target for anti-NED strategies and combination therapy with AR inhibitors.
Keywords:
Monoamine oxidase ANeuroendocrine differentiationProstate cancer

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.2K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Adrenergic Neurons: Neurotransmission01:27

Adrenergic Neurons: Neurotransmission

Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
4.4K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.3K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.2K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.0K